Corcept Therapeutics (HAM:HTD) Ending Cash Position: €95.1 Mil (As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

HAM:HTD Corcept Therapeutics Inc HAM:HTD
88 GF Score
Price €75.32
GF Value €52.76
! 8 Warning Signs
View Full Analysis

What is Corcept Therapeutics Ending Cash Position?

Corcept Therapeutics HAM:HTD -4.78% 88 Ending Cash Position is €95.1 Mil as of Mar. 2026. GuruFocus rates HAM:HTD with a GF Score™ of 88/100 and a GF Value™ of €52.76. The stock has 8 warning signs investors should review.

Corcept Therapeutics's Ending Cash Position for the quarter that ended in Mar. 2026 was €95.1 Mil.

Corcept Therapeutics's quarterly Ending Cash Position declined from Sep. 2025 (€106.6 Mil) to Dec. 2025 (€102.9 Mil) and declined from Dec. 2025 (€102.9 Mil) to Mar. 2026 (€95.1 Mil).

Corcept Therapeutics's annual Ending Cash Position declined from Dec. 2023 (€124.3 Mil) to Dec. 2024 (€121.9 Mil) and declined from Dec. 2024 (€121.9 Mil) to Dec. 2025 (€102.9 Mil).

Corcept Therapeutics Ending Cash Position Related Terms

Corcept Therapeutics Ending Cash Position Historical Data

* Premium members only.

The historical data trend for Corcept Therapeutics's Ending Cash Position can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Corcept Therapeutics Ending Cash Position Chart

Corcept Therapeutics Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Ending Cash Position
Get a 7-Day Free Trial Premium Member Only Premium Member Only 68.69 62.62 124.30 121.92 102.90

Corcept Therapeutics Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Ending Cash Position Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 84.01 89.08 106.62 102.90 95.14
HAM:HTD
88GF Score
Corcept Therapeutics Inc HAM:HTD
Ending Cash Position is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Corcept Therapeutics Ending Cash Position Calculation

Ending Cash Position is the cash and cash equivalents balance at the end of the accounting period, as indicated on the Cash Flow statement. It is equal to the Beginning Cash Position plus the Net Change in Cash.

Corcept Therapeutics's Ending Cash Position for the fiscal year that ended in Dec. 2025 is calculated as

Ending Cash Position= Beginning Cash Position+Net Change in Cash
=109.027+-6.124
=102.9

Corcept Therapeutics's Ending Cash Position for the quarter that ended in Mar. 2026 is calculated as

Ending Cash Position=Beginning Cash Position+Net Change in Cash
=105.31+-10.17
=95.1

Frequently Asked Questions Learn more about Ending Cash Position →
What does a Ending Cash Position of €95.1 Mil mean?
Corcept Therapeutics (HAM:HTD) has a Ending Cash Position of €95.1 Mil as of Mar. 2026. Ending Cash Position is the cash and cash equivalents balance at the end of the accounting period, as indicated on the Cash Flow statement. View historical data on Corcept Therapeutics and its competitors.
Is Corcept Therapeutics' Ending Cash Position too high?
Corcept Therapeutics' current Ending Cash Position is €95.1 Mil. Overall, Corcept Therapeutics has a GF Score™ of 88/100, reflecting its overall financial health beyond just this single metric.
How does Corcept Therapeutics' Ending Cash Position compare to PRAX and IBRX?
Corcept Therapeutics' Ending Cash Position of €95.1 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Ending Cash Position for a Biotechnology company?
A good Ending Cash Position depends on the Biotechnology industry context. However, Ending Cash Position should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Ending Cash Position mean?
A high Ending Cash Position can signal that a stock is expensive relative to its fundamentals. Ending Cash Position is the cash and cash equivalents balance at the end of the accounting period, as indicated on the Cash Flow statement. View historical data on Corcept Therapeutics and its competitors. Corcept Therapeutics's current Ending Cash Position is €95.1 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Corcept Therapeutics stock overvalued right now?
Corcept Therapeutics (HAM:HTD) has a current Ending Cash Position of €95.1 Mil. The stock's GF Value™ is €52.76, compared to a current price of €75.32 — trading 42.8% above its estimated fair value. The current Ending Cash Position is €95.1 Mil. Corcept Therapeutics' overall GF Score™ is 88/100 with 8 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Ending Cash Position calculated?
Ending Cash Position is calculated from a company's financial statements. For Corcept Therapeutics (HAM:HTD), the current Ending Cash Position is €95.1 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Corcept Therapeutics (HAM:HTD) Overvalued in 2026?

Based on GuruFocus' analysis, Corcept Therapeutics stock appears to be overvalued. The current stock price of €75.32 is trading 42.8% above its estimated GF Value™ of €52.76.

Key valuation signals for HAM:HTD:

  • Ending Cash Position: €95.1 Mil
  • GF Value™: €52.76 vs. price of €75.32 (42.8% above fair value)
  • GF Score™: 88/100 with 8 warning signs

No single metric tells the full story. See the HAM:HTD stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Corcept Therapeutics Business Description

Address 101 Redwood Shores Parkway, Redwood City, CA, USA, 94065
Corcept Therapeutics Inc is a commercial-stage pharmaceutical company engaged in the discovery and development of medications that treat severe metabolic, oncologic, and neuropsychiatric disorders by modulating the effect of the cortisol hormone. The company markets Korlym (mifepristone) tablets and its authorized generic version, which is an oral medication for the treatment of hypercortisolism (also known as Cushing's syndrome). Additionally, its pipeline contains several key compounds, such as Relacorilant, Dazucorilant, Miricorilant, etc., that are being evaluated in clinical trials as potential treatments for a variety of serious disorders like hypercortisolism, solid tumors (including ovarian, endometrial, cervical, pancreatic, and prostate cancers), ALS, and MASH.
88GF Score

Get the complete analysis for HAM:HTD

Ending Cash Position is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€75.32
Price
€52.76
GF Value